Rigel Pharmaceuticals chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.50
Dividend & YieldN/A$ (N/A)
Beta 1.3
Market capitalization 120.97M
Operating cash flow -70.94M
ESG Scores unknown

Company description

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio2.33
Working Capital-0.2
Return On Equity-0.59
Debt To Equity2.39
Fixed Asset Ratio3.14
Fixed Interest Cover-4.01

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 6.19M 22.02M -23.96M -381k
Total Cashflows From Investing Activities 24.96M -23.66M 47.47M -80.04M
Net Borrowings 9.79M 9.79M 9.97M
Total Cash From Financing Activities 71.89M 11.37M 12.57M 62.67M
Change To Operating Activities 2.85M 1.04M -374k 14.47M
Issuance Of Stock 71.89M 1.58M 2.6M 62.67M
Net Income -70.48M -66.89M -29.74M -17.91M
Change In Cash 38.03M -53.8M 7.85M -11.48M
Effect Of Exchange Rate
Total Cash From Operating Activities -58.83M -41.51M -52.19M 5.88M
Depreciation 594k 683k 706k 1.06M
Change To Account Receivables -4.08M -6.03M -5.86M 501k
Other Cashflows From Financing Activities
Change To Netincome 6.94M 8.04M 7.17M 13.01M
Capital Expenditures -1.11M -1.46M -1.26M -627k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 46.9M 52.88M
Income Before Tax -70.48M -66.89M -29.74M -17.31M
Net Income -70.48M -66.89M -29.74M -17.91M
Selling General Administrative 70M 74.59M 76.6M 91.89M
Gross Profit -2.68M 5.5M 47.62M 72.42M
Ebit -72.68M -69.09M -28.97M -19.48M
Operating Income -72.68M -69.09M -28.97M -19.48M
Interest Expense -335k -335k -1.35M -4.86M
Income Tax Expense 605k
Total Revenue 44.51M 59.29M 108.62M 138.74M
Cost Of Revenue 47.19M 53.79M 61M 66.32M
Total Other Income ExpenseNet 2.2M 2.2M -771k 2.17M
Net Income From Continuing Ops -70.48M -66.89M -29.74M -17.91M
Net Income Applicable To Common Shares -70.48M -66.89M -29.74M -17.91M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 29.23M 93.75M 76.35M 136.95M
Total Stockholder Equity 109.88M 53.81M 34.03M 30.37M
Other Current Liabilities 1.2M 25.53M 4.51M 10.75M
Total Assets 139.11M 147.57M 110.38M 167.33M
Common Stock 167k 168k 169k 172k
Other Current Assets
Retained Earnings -1.21B -1.28B -1.31B -1.32B
Treasury Stock -24k 23k -4k -102k
Cash 76.32M 22.52M 30.37M 18.89M
Total Current Liabilities 27.73M 58.21M 40.84M 63.55M
Other Stockholder Equity -24k 23k -4k -102k
Property, Plant, and Equipment 1.39M 27.87M 20.57M 11.89M
Total Current Assets 136.99M 119M 88.98M 154.47M
Net Tangible Assets 109.88M 53.81M 34.03M 30.37M
Net Receivables 4.08M 10.11M 15.97M 15.47M
Accounts Payable 6.39M 4.15M 3.71M 3.79M


Insider Transactions

Here are the insider transactions of stock shares related to Rigel Pharmaceuticals:

Filer Name Transaction Text Ownership Date Filer Relation Shares
RODRIGUEZ RAUL RPurchase at price 0.69 per share.D2022-06-09Chief Executive Officer1M
MOOS WALTER HStock Award(Grant) at price 0.00 per share.D2022-05-20Director25k
LYONS GARY AStock Award(Grant) at price 0.00 per share.D2022-05-20Director25k
LAPOINTE ANTHONY GREGGStock Award(Grant) at price 0.00 per share.D2022-05-20Director25k
WASMAN JANEStock Award(Grant) at price 0.00 per share.D2022-05-20Director25k
HANNAH ALISON L.Stock Award(Grant) at price 0.00 per share.D2022-05-20Director25k
ALI-JACKSON KAMILStock Award(Grant) at price 0.00 per share.D2022-05-20Director18.75k
KOTZIN BRIAN LStock Award(Grant) at price 0.00 per share.D2022-05-20Director25k
RODRIGUEZ RAUL RStock Award(Grant) at price 0.00 per share.D2022-01-24Chief Executive Officer200k
VANCE DOLLY AStock Award(Grant) at price 0.00 per share.D2022-01-24General Counsel50k
SCHORNO DEAN LStock Award(Grant) at price 0.00 per share.D2022-01-24Chief Financial Officer50k
DUMMER WOLFGANGStock Award(Grant) at price 0.00 per share.D2022-01-24Officer50k
SANTOS DAVID AStock Award(Grant) at price 0.00 per share.D2022-01-24Officer50k
GOODWIN BRADFORD SStock Award(Grant) at price 0.00 per share.D2021-05-19Director25k
MOOS WALTER HStock Award(Grant) at price 0.00 per share.D2021-05-19Director25k
LYONS GARY AStock Award(Grant) at price 0.00 per share.D2021-05-19Director25k
LAPOINTE ANTHONY GREGGStock Award(Grant) at price 0.00 per share.D2021-05-19Director25k
WASMAN JANEStock Award(Grant) at price 0.00 per share.D2021-05-19Director25k
HANNAH ALISON L.Stock Award(Grant) at price 0.00 per share.D2021-05-19Director6.25k
KOTZIN BRIAN LStock Award(Grant) at price 0.00 per share.D2021-05-19Director25k
KATKIN KEITH AStock Award(Grant) at price 0.00 per share.D2021-05-19Director25k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Rigel Pharmaceuticals. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Rigel Pharmaceuticals

Here is the result of two systematic investment strategies applied to Rigel Pharmaceuticals. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Rigel Pharmaceuticals

The following chart shows the equity curve of the two systematic investment strategies applied to Rigel Pharmaceuticals:

Rigel Pharmaceuticals automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 40.01% on the backtest period.

Performance at glance

Performance

40.01 %

Latent gain

899.94 $

Invested capital

2249.14 $

Annualized return

9.66 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Rigel Pharmaceuticals

This is the result of two momentum investment strategies applied to Rigel Pharmaceuticals. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Rigel Pharmaceuticals

The following chart shows all the entries opened by the momentum investment system on Rigel Pharmaceuticals:

Rigel Pharmaceuticals momentum entries
  • The first momentum investment strategy would give 56.88% of return on Rigel Pharmaceuticals. That represents 3128.42$ of latent gain with 5499.76$ of employed capital.
  • The second momentum investment strategy would give 47.84% of return on Rigel Pharmaceuticals. That represents 2150.49$ of latent gain with 4495.49$ of employed capital.
Performance at glance (1Q Momentum)

Performance

56.88 %

Latent gain

3128.42 $

Invested capital

5499.76 $

Annualized return

50.07 %
Performance at glance (2Q Momentum)

Performance

47.84 %

Latent gain

2150.49 $

Invested capital

4495.49 $

Annualized return

13.07 %

Momentum equity curve on Rigel Pharmaceuticals

The following chart shows the equity curve of the two momentum strategies applied to Rigel Pharmaceuticals:

Rigel Pharmaceuticals momentum equity

Note: the dividends potentially given by Rigel Pharmaceuticals are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Rigel Pharmaceuticals

The following chart shows the employed capital evolution of the two momentum strategies on Rigel Pharmaceuticals since the beginning:

Rigel Pharmaceuticals

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Rigel Pharmaceuticals

Buy the dip entry openings on Rigel Pharmaceuticals

Rigel Pharmaceuticals

The performance achieved by the robo-advisor on Rigel Pharmaceuticals is 107.15%. That represents 802.84$ of latent gain with 749.26$ of employed capital. The following chart shows Rigel Pharmaceuticals stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Rigel Pharmaceuticals, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

107.15 %

Latent gain

802.84 $

Invested capital

749.26 $

Annualized return

50.07 %

Equity curve of the strategy applied to Rigel Pharmaceuticals

The following chart shows the result of the investment strategy applied to Rigel Pharmaceuticals:

Rigel Pharmaceuticals

Note: the dividends potentially given by Rigel Pharmaceuticals are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Rigel Pharmaceuticals

The following chart shows the employed capital evolution since the beginning of the investment strategy on Rigel Pharmaceuticals:

Rigel Pharmaceuticals

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Rigel Pharmaceuticals

In this section, I will compare the three previous investment strategies applied to Rigel Pharmaceuticals.

Equity curve comparison on Rigel Pharmaceuticals

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Rigel Pharmaceuticals investment strategy comparison

Employed capital comparison on Rigel Pharmaceuticals

Rigel Pharmaceuticals investment comparison

Performance comparison on Rigel Pharmaceuticals

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 40.01% 899.94$ 2249.14$ 9.66%
Momentum 1 quarter 56.88% 3128.42$ 5499.76$ 14.58%
Momentum 2 quarters 47.84% 2150.49$ 4495.49$ 13.07%
Non-directional 107.15% 802.84$ 749.26$ 50.07%
Annualized return comparison

Automatic investment

9.66 %

Momentum 1Q

13.07 %

Momentum 2Q

13.07 %

Non-directional

50.07 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Rigel Pharmaceuticals:

Positive correlations

Most correlated stocks this year

  • Rigel Pharmaceuticals

  • Most correlated stocks last 3 months

  • Stanley Black & Decker Inc - Unit
  • Forrester Research Inc
  • First Bancorp Inc (ME)
  • WYNNSTAY GROUP PLC ORD 25P
  • L.B. Foster Co. - Class A
  • Diamond Hill Investment Group Inc - Class A
  • Resolute Forest Products Inc
  • Universal Insurance Holdings Inc
  • Tupperware Brands Corporation
  • WestRock Company
  • Standard Motor Products Inc
  • Arrow Financial Corp
  • Luther Burbank Corp
  • Insteel Industries Inc
  • Matthews International Corp - Class A
  • Stanley Black & Decker Inc
  • First Foundation Inc
  • Verizon Communications Inc
  • Freeport-McMoRan Inc
  • Crocs Inc
  • Oppenheimer Holdings Inc - Class A
  • Topgolf Callaway Brands Corp
  • Core Laboratories N.V.
  • Global X SuperDividend ETF
  • Universal Stainless & Alloy Products Inc
  • Snap-on Inc
  • INVESCO INTERNATIONAL BUYBACK ACHIEVERS ETF
  • UMH Properties Inc
  • IShares MSCI Emerging Markets ex China ETF
  • Capri Holdings Ltd
  • Hasbro Inc
  • iShares MSCI Ireland ETF
  • Franklin Electric Co. Inc
  • Universal Corp
  • Curtiss-Wright Corp
  • WEIR GROUP PLC ORD 12.5P
  • Lincoln Electric Holdings Inc
  • Autoliv Inc
  • LyondellBasell Industries NV - Class A
  • Emerson Electric Company
  • JELD-WEN Holding Inc
  • Encore Wire Corp
  • DXP Enterprises Inc
  • First Bancorp PR
  • Forward Air Corp
  • Mosaic Company
  • Mueller Industries Inc
  • Invesco S&P SmallCap Materials ETF
  • Invesco S&P 500 Equal Weight Materials ETF
  • Invesco S&P SmallCap 600 Pure Value ETF
  • Scansource Inc
  • ITT Inc
  • Robert Half International Inc
  • Avient Corp
  • Whirlpool Corp
  • J.B. Hunt Transport Services Inc
  • MACOM Technology Solutions Holdings Inc
  • Paccar Inc
  • TE Connectivity Ltd
  • Donaldson Co. Inc
  • Oxford Industries Inc
  • Sensient Technologies Corp
  • Sierra Bancorp
  • Trico Bancshares
  • O-I Glass Inc
  • Ingevity Corp
  • Invesco S&P SmallCap Information Technology ETF
  • Kaman Corp
  • PPG Industries Inc
  • Flowserve Corp
  • VICTORYSHARES INTERNATIONAL HIGH DIV VOLATILITY WT
  • First Trust RiverFront Dynamic Developed Internati
  • Vanguard International High Dividend Yield ETF
  • VICTORYSHARES INTERNATIONAL VOLATILITY WTD ETF
  • Schwab International Equity ETF
  • SPDR Portfolio Developed World ex-US ETF
  • Crane Holdings Company
  • AGCO Corp
  • Marriott International Inc - Class A
  • Sonoco Products Company
  • iShares Trust iShares ESG Aware MSCI EAFE ETF
  • Vishay Precision Group Inc
  • Barrett Business Services Inc
  • Summit Materials Inc - Class A
  • Clearfield Inc
  • Minerals Technologies Inc
  • American Vanguard Corp
  • Trimas Corporation
  • Innospec Inc
  • Myers Industries Inc
  • Acuity Brands Inc
  • Miller Industries Inc
  • Canadian National Railway Company
  • Hibbett Inc
  • Fortive Corp
  • Genpact Ltd
  • Arlo Technologies Inc
  • ISHARES INDIA 50 ETF
  • Woori Financial Group Inc
  • Shinhan Financial Group Co. Ltd
  • DZS Inc
  • iMedia Brands Inc - Class A
  • Rush Enterprises Inc - Class A
  • Rush Enterprises Inc - Class B
  • JAGUAR MINING INC
  • H.B. Fuller Company
  • CRH Plc
  • H&E Equipment Services Inc
  • Fabrinet
  • Gap Inc
  • Invesco RAFI Strategic Developed ex-US ETF
  • Rigel Pharmaceuticals
  • Pediatrix Medical Group Inc
  • Liberty TripAdvisor Holdings Inc - Series A
  • Almaden Minerals Ltd
  • Equitrans Midstream Corporation
  • Graham Holdings Co. - Class B
  • POSCO Holdings Inc
  • Valvoline Inc
  • Deere & Company
  • Radware
  • CGI Inc - Class A
  • Titan Machinery Inc
  • Maximus Inc
  • 3M Company
  • Leggett & Platt Inc
  • Union Pacific Corp
  • Armada Hoffler Properties Inc
  • Cactus Inc - Class A
  • Hudbay Minerals Inc
  • Mettler-Toledo International Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between Rigel Pharmaceuticals and the other stocks. There may be false positives or some missing correlated stocks. If the price of Rigel Pharmaceuticals does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Rigel Pharmaceuticals
    Country United States
    City South San Francisco
    Address 1180 Veterans Boulevard
    Phone 650 624 1100
    Website www.rigel.com
    FullTime employees 165
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker RIGL
    Market www.nasdaq.com

    Rigel Pharmaceuticals ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown